Munoz-Gamez et al.[52] have reported that the PARPi 4-amino-1,8-naphthalimide enhances the doxorubicin chemosensitivity in hepatocellular carcinoma cells by increasing apoptosis while reducing EGFR and Bcl-xL expressions. This evidence concerns the gene BCL2L1 and hepatocellular carcinoma.